Oaxaca Site Management Organization S.C. (OSMO)
Oaxaca Site Management Organization S.C. (OSMO)
Humboldt 302, ruta Independencia, Colonia Centro, Oaxaca de Juárez, Oaxaca. México. CP 68000
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Andrea Alicia Colli Domínguez
Alonso Fuentes Rivera
Alberto Ali Vicente Villavicencio
Elizabeth Vargas Mora
Flor Citlali Rojas Ramírez
Sergio Garcia Mendez
Jessica Trujillo Martínez
Belem Deyanira Rendón González
Víctor C. Bohórquez López
Ana Laura Flores Barranco
Lucia Cruz Aquino
Red OSMO
Open studies
Lung cancer
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer - PROCLAIM 20170770 - Iqvia Rds ChileSee more
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors - CDK4i - PfizerSee more
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) - MK 2870-007 - Merck Sharp & Dohme LLCSee more
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) - MK-2870-019 - Merck Sharp & Dohme LLCSee more
A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004) - MK-1084-004 - Merck Sharp & Dohme LLCSee more
Breast Cancer
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer - PROCLAIM 20170770 - Iqvia Rds ChileSee more
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer - EMBER-4 - Eli Lilly and CompanySee more
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors - CDK4i - PfizerSee more
Pulmonary fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis - ALOFT-IPF - Bristol-Myers SquibbSee more
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis - ALOFT-PPF - Bristol-Myers SquibbSee more
Colorectal cancer
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors - CDK4i - PfizerSee more
Liposarcoma
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors - CDK4i - PfizerSee more
Lupus
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus - POETYK SLE-2 - Bristol-Myers SquibbSee more
Ovarian cancer
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer - PROCLAIM 20170770 - Iqvia Rds ChileSee more
Prostate cancer
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors - CDK4i - PfizerSee more
Pubertal Development Disorder
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial) - LIBELULA - Debiopharm International SASee more
Rare diseases
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity - Oasiz - Horizon Therapeutics Ireland DACSee more
Solid tumors
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors - CDK4i - PfizerSee more
Ulcerative colitis
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) - MK-7240-001 - Merck Sharp & Dohme LLCSee more
